Minimal Residual Disease Testing Market - Global Forecast to 2029
商品番号 : SMB-
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年12月 |
| ページ数 | 246 |
| 図表数 | 316 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The MRD testing market will rise in value from estimated USD 1.43 Billion in 2024 to USD 2.55 Billion in 2029, at a CAGR of 12.2% over the forecast period. Increased funding and grants for cancer control programs across the globe have emerged as an important growth factor in the MRD testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of cancer, especially in terms of early detection and prevention.
MRD検査市場の価値は、2024年の推定14億3,000万米ドルから2029年には25億5,000万米ドルへと、予測期間中に12.2%のCAGRで増加すると予想されます。世界中のがん対策プログラムへの資金提供と助成金の増加が、MRD検査市場の重要な成長要因として浮上しています。現在、特に早期発見と予防の観点から、増大するがんの負担に対処するために、各国政府やWHOや世界基金などの国際機関が多額の資金提供を行っています。
These funds are being channelled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of cancer. Apart from that, research grants and international collaborations are also enabling cancer testing integration into routine health care services. Thus, this growing funding is rendering MRD tests available and enhancing the efforts to control cancer globally. This, in turn, is fuelling the growth of the global minimal residual disease testing market.
“MRD Assay Kits & Reagents segment is expected to have the fastest growth rate in the MRD testing market, by product, during the forecast period.”
The MRD testing market is segmented into assay kits & reagents, and instruments based on product. Assay kits & reagents are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy of tests. Growing penetration of these tests in high-risk populations, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in cancer and advancements in diagnostics are also driving the high growth of the test kits segment in the MRD testing market.
“Haematological malignancies segment accounted for the highest growth rate in the MRD testing market, by application, during the forecast period.”
Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.
“Asia Pacific: The fastest-growing region in MRD testing market.”
The worldwide market for MRD testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drives the need for essential cancer screening and management. Growth in government and international organization funding and campaigns against cancer has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of cancer has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the MRD testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the MRD testing market in the Asia Pacific region.
The break-up of the profile of primary participants in the MRD testing market:
- By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
- By Designation: Managers – 30%, D-level – 50%, and Others – 20%
- By Region: North America – 51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and Others – 4%
The key players in this market are are F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China).
Research Coverage:
This research report categorizes the MRD testing market by product (assay kits & reagents, instruments), by technology (PCR, NGS, flow cytometry, and other applications), by application (hematological malignancies, solid tumors, multiple myeloma, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the MRD testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the MRD testing market. Competitive analysis of upcoming startups in the MRD testing market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall MRD testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising incidence of cancer, and increased funding and grants for cancer control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the MRD testing market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the MRD testing market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the MRD testing market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the MRD testing market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US).
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED & REGIONAL SCOPE 27
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.2 RESEARCH APPROACH 31
2.2.1 SECONDARY DATA 32
2.2.1.1 Key data from secondary sources 32
2.2.2 PRIMARY DATA 33
2.2.2.1 Primary sources 34
2.2.2.2 Key data from primary sources 34
2.2.2.3 Key industry insights 35
2.2.2.4 Breakdown of primary interviews 35
2.3 MARKET SIZE ESTIMATION 36
2.3.1 BOTTOM-UP APPROACH 37
2.3.1.1 Approach 1: Company revenue estimation 37
2.3.1.2 Approach 2: Presentations of companies and primary interviews 37
2.3.1.3 Growth forecast 38
2.3.1.4 CAGR projections 38
2.3.2 TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 40
2.5 MARKET SHARE ESTIMATION 40
2.6 STUDY ASSUMPTIONS 41
2.7 GROWTH RATE ASSUMPTIONS 41
2.8 RESEARCH LIMITATIONS 42
2.9 RISK ASSESSMENT 42
2.9.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 47
4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW 47
4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY PRODUCT, 2024 VS. 2029 48
4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY,
2024 VS. 2029 48
4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION,
2024 VS. 2029 49
4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2024 VS. 2029 49
4.6 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Rising incidence of hematological malignancies 52
5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers 52
5.2.1.3 Increasing cancer awareness initiatives by global health organizations 53
5.2.2 RESTRAINTS 54
5.2.2.1 Complex regulatory frameworks delaying approvals of new molecular diagnostics tests 54
5.2.2.2 High cost of minimal residual disease testing kits 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Growth opportunities in emerging countries 54
5.2.4 CHALLENGES 55
5.2.4.1 Unclear reimbursement scenario and policies for patients 55
5.3 PRICING ANALYSIS 56
5.3.1 INDICATIVE PRICING TREND OF KEY PLAYERS, BY PRODUCT & REGION 56
5.4 PATENT ANALYSIS 58
5.4.1 LIST OF MAJOR PATENTS 59
5.5 VALUE CHAIN ANALYSIS 60
5.6 SUPPLY CHAIN ANALYSIS 61
5.7 TRADE ANALYSIS 62
5.7.1 IMPORT DATA 62
5.7.2 EXPORT DATA 63
5.8 ECOSYSTEM ANALYSIS 63
5.8.1 ROLE IN ECOSYSTEM 64
5.9 PORTER’S FIVE FORCES ANALYSIS 64
5.9.1 THREAT OF NEW ENTRANTS 65
5.9.2 THREAT OF SUBSTITUTES 65
5.9.3 BARGAINING POWER OF BUYERS 66
5.9.4 BARGAINING POWER OF SUPPLIERS 66
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 67
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 67
5.10.2 BUYING CRITERIA 68
5.11 REGULATORY ANALYSIS 69
5.11.1 REGULATORY LANDSCAPE 69
5.11.1.1 North America 69
5.11.1.1.1 US 69
5.11.1.1.2 Canada 69
5.11.1.2 Europe 69
5.11.1.3 Asia Pacific 70
5.11.1.3.1 China 70
5.11.1.3.2 Japan 71
5.11.1.4 Latin America 72
5.11.1.4.1 Brazil 72
5.11.1.4.2 Mexico 72
5.11.1.5 Middle East 73
5.11.1.6 Africa 73
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
5.12 TECHNOLOGY ANALYSIS 75
5.12.1 KEY TECHNOLOGIES 75
5.12.1.1 PCR and NGS 75
5.12.2 ADJACENT TECHNOLOGIES 76
5.12.2.1 Digital PCR 76
5.13 KEY CONFERENCES & EVENTS IN 2023–2024 76
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.15 INVESTMENT & FUNDING SCENARIO 79
5.16 CASE STUDY ANALYSIS 79
5.17 IMPACT OF AI/GEN AI ON MINIMAL RESIDUAL DISEASE TESTING MARKET 80
6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT 82
6.1 INTRODUCTION 83
6.2 ASSAY KITS & REAGENTS 83
6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET 83
6.3 INSTRUMENTS 85
6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO DRIVE MARKET GROWTH 85
7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY 86
7.1 INTRODUCTION 87
7.2 POLYMERASE CHAIN REACTION 87
7.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION 87
7.3 NEXT-GENERATION SEQUENCING 88
7.3.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO SUPPORT ADOPTION 88
7.4 FLOW CYTOMETRY 89
7.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO PROPEL MARKET GROWTH 89
7.5 OTHER TECHNOLOGIES 90
8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION 92
8.1 INTRODUCTION 93
8.2 HEMATOLOGICAL MALIGNANCIES 93
8.2.1 LEUKEMIA 95
8.2.1.1 Myeloid leukemia 98
8.2.1.1.1 High prevalence of AML in adults to support growth 98
8.2.1.2 Lymphocytic leukemia 100
8.2.1.2.1 High incidence of ALL in children to drive market 100
8.2.1.3 Other leukemias 103
8.2.2 LYMPHOMA 105
8.2.2.1 Non-Hodgkin lymphoma 108
8.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth 108
8.2.2.2 Hodgkin lymphoma 110
8.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel demand for MRD testing 110
8.3 SOLID TUMORS 112
8.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH 112
8.4 MULTIPLE MYELOMA 114
8.4.1 RISING INCIDENCE OF MULTIPLE MYELOMAS TO DRIVE MARKET 114
8.5 OTHER APPLICATIONS 116
9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER 119
9.1 INTRODUCTION 120
9.2 HOSPITALS & SPECIALTY CLINICS 120
9.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH 120
9.3 DIAGNOSTIC LABORATORIES 121
9.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH 121
9.4 ACADEMIC & RESEARCH INSTITUTES 122
9.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET 122
9.5 OTHER END USERS 123
10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION 124
10.1 INTRODUCTION 125
10.2 NORTH AMERICA 125
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 129
10.2.2 US 129
10.2.2.1 Increasing prevalence of cancer to drive market 129
10.2.3 CANADA 132
10.2.3.1 Availability of various cancer screening programs to support market growth 132
10.3 EUROPE 136
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 136
10.3.2 GERMANY 140
10.3.2.1 Government support for research funding to support MRD testing market 140
10.3.3 UK 143
10.3.3.1 Increasing number of diagnostic laboratories to propel market growth 143
10.3.4 FRANCE 146
10.3.4.1 Rising R&D expenditure in France to drive market 146
10.3.5 ITALY 149
10.3.5.1 Favorable funding scenario to drive market 149
10.3.6 SPAIN 152
10.3.6.1 Consolidation of laboratories in Spain to support market growth 152
10.3.7 REST OF EUROPE 155
10.4 ASIA PACIFIC 158
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 158
10.4.2 CHINA 163
10.4.2.1 Growing public access to advanced healthcare facilities to drive market 163
10.4.3 JAPAN 166
10.4.3.1 Universal healthcare reimbursement policy to support market growth 166
10.4.4 INDIA 169
10.4.4.1 Increasing private and public investments in healthcare system to drive market 169
10.4.5 REST OF ASIA PACIFIC 172
10.5 LATIN AMERICA 176
10.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET 176
10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 176
10.6 MIDDLE EAST & AFRICA 179
10.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET 179
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 180
10.7 GCC COUNTRIES 183
10.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE AND FUNDING IN RESEARCH TO DRIVE GCC MARKET 183
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 183
11 COMPETITIVE LANDSCAPE 187
11.1 OVERVIEW 187
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 187
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 187
11.3 REVENUE ANALYSIS, 2019–2023 190
11.4 MARKET SHARE ANALYSIS, 2023 191
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 193
11.5.1 LIST OF EVALUATED VENDORS 193
11.5.2 STARS 193
11.5.3 EMERGING LEADERS 193
11.5.4 PERVASIVE PLAYERS 193
11.5.5 PARTICIPANTS 193
11.5.6 COMPANY FOOTPRINT: KEY PLAYERS, 2023 195
11.5.6.1 Company footprint 195
11.5.6.2 Product footprint 195
11.5.6.3 Technology footprint 196
11.5.6.4 Application footprint 196
11.5.6.5 Region footprint 197
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 197
11.6.1 PROGRESSIVE COMPANIES 197
11.6.2 RESPONSIVE COMPANIES 197
11.6.3 DYNAMIC COMPANIES 197
11.6.4 STARTING BLOCKS 198
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 199
11.7 COMPANY VALUATION & FINANCIAL METRICS 201
11.8 BRAND/PRODUCT COMPARISON 202
11.9 COMPETITIVE SCENARIO 203
11.9.1 PRODUCT LAUNCHES 203
11.9.2 DEALS 204
12 COMPANY PROFILES 206
12.1 KEY PLAYERS 206
12.1.1 F. HOFFMANN-LA ROCHE AG 206
12.1.1.1 Business overview 206
12.1.1.2 Products offered 207
12.1.1.3 Recent developments 208
12.1.1.3.1 Product launches 208
12.1.1.4 MnM view 208
12.1.1.4.1 Right to win 208
12.1.1.4.2 Strategic choices 208
12.1.1.4.3 Weaknesses & competitive threats 208
12.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS 209
12.1.2.1 Business overview 209
12.1.2.2 Products offered 210
12.1.2.3 Recent developments 211
12.1.2.3.1 Deals 211
12.1.2.4 MnM view 211
12.1.2.4.1 Right to win 211
12.1.2.4.2 Strategic choices 211
12.1.2.4.3 Weaknesses & competitive threats 211
12.1.3 GUARDANT HEALTH, INC. 212
12.1.3.1 Business overview 212
12.1.3.2 Products offered 213
12.1.3.3 Recent developments 214
12.1.3.3.1 Product launches & approvals 214
12.1.3.3.2 Deals 215
12.1.3.4 MnM view 215
12.1.3.4.1 Right to win 215
12.1.3.4.2 Strategic choices 215
12.1.3.4.3 Weaknesses & competitive threats 215
12.1.4 SYSMEX CORPORATION 216
12.1.4.1 Business overview 216
12.1.4.2 Products offered 217
12.1.4.3 Recent developments 217
12.1.4.3.1 Product launches 217
12.1.4.4 MnM view 218
12.1.4.4.1 Right to win 218
12.1.4.4.2 Strategic choices 218
12.1.4.4.3 Weaknesses & competitive threats 218
12.1.5 NEOGENOMICS LABORATORIES 219
12.1.5.1 Business overview 219
12.1.5.2 Products offered 219
12.1.5.3 Recent developments 220
12.1.5.3.1 Deals 220
12.1.5.4 MnM view 220
12.1.5.4.1 Right to win 220
12.1.5.4.2 Strategic choices 220
12.1.5.4.3 Weaknesses & competitive threats 220
12.1.6 MOLECULARMD (A SUBSIDIARY OF ICON PLC) 221
12.1.6.1 Business overview 221
12.1.6.2 Products offered 222
12.1.7 ADAPTIVE BIOTECHNOLOGIES 223
12.1.7.1 Business overview 223
12.1.7.2 Products offered 224
12.1.7.3 Recent developments 224
12.1.7.3.1 Deals 224
12.1.8 ARCHERDX (INVITAE CORPORATION) 225
12.1.8.1 Business overview 225
12.1.8.2 Products offered 226
12.1.8.3 Recent developments 227
12.1.8.3.1 Product launches 227
12.1.8.3.2 Deals 227
12.1.9 BIO-RAD LABORATORIES, INC. 228
12.1.9.1 Business overview 228
12.1.9.2 Products offered 229
12.1.10 NATERA, INC. 230
12.1.10.1 Business overview 230
12.1.10.2 Products offered 231
12.2 OTHER PLAYERS 232
12.2.1 OPKO HEALTH, INC. 232
12.2.2 GENETRON HEALTH 233
12.2.3 QUEST DIAGNOSTICS, INC. 234
12.2.4 ASURAGEN, INC. 235
12.2.5 INVIVOSCRIBE, INC. 236
12.2.6 ARUP LABORATORIES INC. 237
12.2.7 MISSION BIO, INC. 237
12.2.8 CERGENTIS B.V. 238
13 APPENDIX 239
13.1 DISCUSSION GUIDE 239
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
13.3 CUSTOMIZATION OPTIONS 244
13.4 RELATED REPORTS 244
13.5 AUTHOR DETAILS 245
LIST OF TABLES
TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2023 52
TABLE 2 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2023 VS. 2030 55
TABLE 3 INDICATIVE PRICE OF MRD TESTING PRODUCTS, BY PRODUCT & REGION,
2022–2024 57
TABLE 4 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 59
TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION) 62
TABLE 6 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019–2023 (USD MILLION) 63
TABLE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM 64
TABLE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 64
TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS (%) 67
TABLE 10 KEY BUYING CRITERIA FOR MRD TESTS, BY END USER 68
TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES 70
TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 71
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 18 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 76
TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 83
TABLE 20 KEY ASSAY KITS & REAGENTS AVAILABLE IN MARKET 84
TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ASSAY KITS & REAGENTS,
BY REGION, 2022–2029 (USD MILLION) 84
TABLE 22 KEY INSTRUMENTS AVAILABLE IN MARKET 85
TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022–2029 (USD MILLION) 85
TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 87
TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION,
2022–2029 (USD MILLION) 88
TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION,
2022–2029 (USD MILLION) 89
TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY,
BY REGION, 2022–2029 (USD MILLION) 90
TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2022–2029 (USD MILLION) 91
TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 93
TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 93
TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022–2029 (USD MILLION) 94
TABLE 32 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 33 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 34 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE,
2022–2029 (USD MILLION) 96
TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 37 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 38 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY COUNTRY, 2022–2029 (USD MILLION) 97
TABLE 39 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY COUNTRY, 2022–2029 (USD MILLION) 98
TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA,
BY REGION, 2022–2029 (USD MILLION) 98
TABLE 41 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 42 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 43 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 44 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA,
BY REGION, 2022–2029 (USD MILLION) 101
TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 46 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 47 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 48 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS,
BY REGION, 2022–2029 (USD MILLION) 103
TABLE 49 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 50 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 51 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 52 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE,
2022–2029 (USD MILLION) 105
TABLE 53 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 54 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 56 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 57 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 58 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR
NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 59 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 60 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 61 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA,
BY REGION, 2022–2029 (USD MILLION) 110
TABLE 62 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 63 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 64 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022–2029 (USD MILLION) 111
TABLE 65 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 66 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 67 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 68 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 69 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA,
BY REGION, 2022–2029 (USD MILLION) 114
TABLE 70 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 71 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 72 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 73 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 117
TABLE 74 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 75 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 76 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 77 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 120
TABLE 78 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 79 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 80 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 81 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS,
BY REGION, 2022–2029 (USD MILLION) 123
TABLE 82 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION,
2022–2029 (USD MILLION) 125
TABLE 83 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 84 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 127
TABLE 85 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 127
TABLE 86 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 127
TABLE 87 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 128
TABLE 88 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 128
TABLE 89 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 128
TABLE 90 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 129
TABLE 91 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 130
TABLE 92 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 130
TABLE 93 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 131
TABLE 94 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 131
TABLE 95 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 131
TABLE 96 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 132
TABLE 97 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 132
TABLE 98 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 133
TABLE 99 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 133
TABLE 100 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 134
TABLE 101 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 102 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 103 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2022–2029 (USD MILLION) 135
TABLE 104 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 135
TABLE 105 EUROPE: FORECAST OF LEUKEMIA CASES, BY COUNTRY, 2025 VS. 2030 VS. 2035 136
TABLE 106 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 137
TABLE 107 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 137
TABLE 108 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 138
TABLE 109 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 138
TABLE 110 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 138
TABLE 111 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2022–2029 (USD MILLION) 139
TABLE 112 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2022–2029 (USD MILLION) 139
TABLE 113 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 139
TABLE 114 GERMANY: CANCER INCIDENCE, BY TYPE, 2022 140
TABLE 115 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 140
TABLE 116 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 141
TABLE 117 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 141
TABLE 118 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 141
TABLE 119 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 120 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2022–2029 (USD MILLION) 142
TABLE 121 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 142
TABLE 122 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 143
TABLE 123 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 144
TABLE 124 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 144
TABLE 125 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 144
TABLE 126 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 145
TABLE 127 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 145
TABLE 128 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 145
TABLE 129 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 146
TABLE 130 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 146
TABLE 131 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 147
TABLE 132 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 147
TABLE 133 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2022–2029 (USD MILLION) 147
TABLE 134 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2022–2029 (USD MILLION) 148
TABLE 135 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 148
TABLE 136 ITALY: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022 149
TABLE 137 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 149
TABLE 138 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 150
TABLE 139 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 150
TABLE 140 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 150
TABLE 141 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 142 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 151
TABLE 143 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 151
TABLE 144 SPAIN: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022 152
TABLE 145 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 152
TABLE 146 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 153
TABLE 147 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 153
TABLE 148 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 153
TABLE 149 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 150 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 154
TABLE 151 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 154
TABLE 152 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 155
TABLE 153 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 155
TABLE 154 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 156
TABLE 155 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 156 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 156
TABLE 157 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 157
TABLE 158 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 157
TABLE 159 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 160 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 160
TABLE 161 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 160
TABLE 162 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 161
TABLE 163 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 164 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA,
BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 165 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA,
BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 166 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 162
TABLE 167 CHINA: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022 163
TABLE 168 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 163
TABLE 169 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 164
TABLE 170 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 164
TABLE 171 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 172 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 173 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 174 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 165
TABLE 175 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022 166
TABLE 176 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 166
TABLE 177 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 167
TABLE 178 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 167
TABLE 179 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 180 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 181 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 182 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 168
TABLE 183 INDIA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022 169
TABLE 184 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 170
TABLE 185 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 170
TABLE 186 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 170
TABLE 187 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 188 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 189 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 190 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2022–2029 (USD MILLION) 172
TABLE 191 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2023 172
TABLE 192 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 173
TABLE 193 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 173
TABLE 194 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 174
TABLE 195 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 196 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 197 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 198 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY END USER, 2022–2029 (USD MILLION) 175
TABLE 199 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 177
TABLE 200 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 177
TABLE 201 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 177
TABLE 202 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 203 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 204 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 205 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 179
TABLE 206 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 180
TABLE 207 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 180
TABLE 208 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 181
TABLE 209 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 210 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 211 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 212 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY END USER, 2022–2029 (USD MILLION) 182
TABLE 213 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 184
TABLE 214 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 184
TABLE 215 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 184
TABLE 216 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 217 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 218 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 219 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION) 186
TABLE 220 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET 187
TABLE 221 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION 192
TABLE 222 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT FOOTPRINT 195
TABLE 223 MINIMAL RESIDUAL DISEASE TESTING MARKET: TECHNOLOGY FOOTPRINT 196
TABLE 224 MINIMAL RESIDUAL DISEASE TESTING MARKET: APPLICATION FOOTPRINT 196
TABLE 225 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGION FOOTPRINT 197
TABLE 226 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 199
TABLE 227 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY PRODUCT & TECHNOLOGY 199
TABLE 228 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY APPLICATION & END USER 200
TABLE 229 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY REGION 200
TABLE 230 MINIMAL RESIDUAL DISEASE TESTING MARKET, PRODUCT LAUNCHES,
JANUARY 2021–NOVEMBER 2024 203
TABLE 231 MINIMAL RESIDUAL DISEASE TESTING MARKET, DEALS,
JANUARY 2021–NOVEMBER 2024 204
TABLE 232 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW 206
TABLE 233 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED 207
TABLE 234 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES,
JANUARY 2021–NOVEMBER 2024 208
TABLE 235 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW 209
TABLE 236 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS OFFERED 210
TABLE 237 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS,
JANUARY 2021–NOVEMBER 2024 211
TABLE 238 GUARDANT HEALTH, INC.: COMPANY OVERVIEW 212
TABLE 239 GUARDANT HEALTH, INC.: PRODUCTS OFFERED 213
TABLE 240 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–NOVEMBER 2024 214
TABLE 241 GUARDANT HEALTH, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 215
TABLE 242 SYSMEX CORPORATION: COMPANY OVERVIEW 216
TABLE 243 SYSMEX CORPORATION: PRODUCTS OFFERED 217
TABLE 244 SYSMEX CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 217
TABLE 245 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW 219
TABLE 246 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED 219
TABLE 247 NEOGENOMICS LABORATORIES: DEALS, JANUARY 2021–NOVEMBER 2024 220
TABLE 248 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY OVERVIEW 221
TABLE 249 MOLECULARMD (A SUBSIDIARY OF ICON PLC): PRODUCTS OFFERED 222
TABLE 250 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW 223
TABLE 251 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS OFFERED 224
TABLE 252 ADAPTIVE BIOTECHNOLOGIES: DEALS, JANUARY 2021–NOVEMBER 2024 224
TABLE 253 ARCHERDX (INVITAE CORPORATION): COMPANY OVERVIEW 225
TABLE 254 ARCHERDX (INVITAE CORPORATION): PRODUCTS OFFERED 226
TABLE 255 ARCHERDX (INVITAE CORPORATION): PRODUCT LAUNCHES,
JANUARY 2021–NOVEMBER 2024 227
TABLE 256 ARCHERDX (INVITAE CORPORATION): DEALS, JANUARY 2021–NOVEMBER 2024 227
TABLE 257 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 228
TABLE 258 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 229
TABLE 259 NATERA, INC.: COMPANY OVERVIEW 230
TABLE 260 NATERA, INC.: PRODUCTS OFFERED 231
TABLE 261 OPKO HEALTH, INC.: COMPANY OVERVIEW 232
TABLE 262 GENETRON HEALTH: COMPANY OVERVIEW 233
TABLE 263 QUEST DIAGNOSTICS, INC.: COMPANY OVERVIEW 234
TABLE 264 ASURAGEN, INC.: COMPANY OVERVIEW 235
TABLE 265 INVIVOSCRIBE, INC.: COMPANY OVERVIEW 236
TABLE 266 ARUP LABORATORIES INC.: COMPANY OVERVIEW 237
TABLE 267 MISSION BIO, INC.: COMPANY OVERVIEW 237
TABLE 268 CERGENTIS B.V.: COMPANY OVERVIEW 238
LIST OF FIGURES
FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION &
REGIONAL SCOPE 27
FIGURE 2 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN 31
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 35
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 36
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 37
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 38
FIGURE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH 39
FIGURE 8 DATA TRIANGULATION METHODOLOGY 40
FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT,
2024 VS. 2029 (USD MILLION) 43
FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY,
2024 VS. 2029 (USD MILLION) 44
FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 44
FIGURE 12 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 45
FIGURE 13 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION,
2024 VS. 2029 (USD MILLION) 46
FIGURE 14 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 47
FIGURE 15 ASSAY KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2029 48
FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 48
FIGURE 17 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2029 49
FIGURE 18 HOSPITALS & SPECIALTY CLINICS TO BE LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING 49
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 21 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET 58
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 60
FIGURE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS 61
FIGURE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS 63
FIGURE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS 67
FIGURE 27 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS 68
FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
FIGURE 29 DEALS AND FUNDING IN MRD TESTING MARKET 79
FIGURE 30 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT 126
FIGURE 31 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT 159
FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN MINIMAL RESIDUAL DISEASE
TESTING MARKET (2019–2023) 190
FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL
DISEASE TESTING MARKET (2023) 191
FIGURE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY
EVALUATION MATRIX (KEY PLAYERS), 2023 194
FIGURE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY FOOTPRINT 195
FIGURE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY
EVALUATION MATRIX (STARTUPS/SMES), 2023 198
FIGURE 37 EV/EBITDA OF KEY VENDORS 201
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 201
FIGURE 39 BRAND COMPARISON FOR ASSAY KITS & REAGENTS 202
FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2023) 207
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS:
COMPANY SNAPSHOT (2023) 210
FIGURE 42 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2023) 213
FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022) 216
FIGURE 44 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY SNAPSHOT (2023) 221
FIGURE 45 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2023) 223
FIGURE 46 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2022) 226
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 229
FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2023) 231
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11